On October 21, 2020 Boundless Bio, a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, reported it will present a poster at the 2020 American Society of Human Genetics (ASHG) Annual Meeting, which is being held in a virtual format this year due to COVID-19 (Press release, Boundless Bio, OCT 21, 2020, View Source [SID1234568745]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Poster Title: A robust imaging and single-cell sequencing platform to characterize tumor extrachromosomal DNA (ecDNA) in response to therapeutic intervention
Session: 202 – Cancer
Poster #: 2251
Date: October 26, 2020
Time: 6:00 a.m. – 11:59 p.m. ET

About ecDNA

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes. ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies and can be passed to daughter cells asymmetrically during cell division, driving tumor heterogeneity. Cancer cells have the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment resistance. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

On October 21, 2020 Henry Schein, Inc. (Nasdaq: HSIC) reported that it will again support nonprofit organizations dedicated to the fight against cancer through its Practice Pink program (Press release, Henry Schein, OCT 21, 2020, View Source [SID1234568743]). Now in its 14th year, Henry Schein has donated more than $1.7 million through the program towards promoting early cancer detection, improving access to care, and supporting research and prevention efforts. Practice Pink, an international effort, is an initiative of Henry Schein Cares, the Company’s global corporate social responsibility program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Along with non-governmental organizations and supplier partners across North America and Europe, Henry Schein is helping dental and medical health care professionals raise awareness and support for a cure for breast cancer and other cancers by offering its customers a range of pink products, including health care consumables, practice supplies, and apparel. Customers can obtain more information about these products in the Henry Schein Dental and Medical catalogs.

"As part of Henry Schein Cares’ mission, we are dedicated to helping catalyze public-private partnerships and mobilize the resources needed to promote wellness and prevention," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Thanks to our dedicated customers and valued supplier partners who have played a large role in making Practice Pink a success, we have collectively helped promote early cancer detection, improved access to care, and provided financial support to further advance the goals of the organizations we support."

The Practice Pink program supports U.S.-based organizations such as the American Cancer Society, Cohen Children’s Medical Center of Northwell Health, Stony Brook Children’s Hospital, and the Memorial Sloan Kettering/Henry Schein Cares Women’s Health Center. In Europe, the program supports organizations such as the Italian League for the Fight Against Cancer (LILT), Germany-based Brustkrebs Deutschland e.V., and Federacja Stowarzyszeń Amazonki in Poland.

For more information about Practice Pink and Henry Schein Cares, please visit www.henryschein.com/PracticePink.

About Henry Schein Cares

Henry Schein Cares stands on four pillars: engaging Team Schein Members to reach their potential, ensuring accountability by extending ethical business practices to all levels within Henry Schein, promoting environmental sustainability, and expanding access to health care for underserved and at-risk communities around the world. Health care activities supported by Henry Schein Cares focus on three main areas: advancing wellness, building capacity in the delivery of health care services, and assisting in emergency preparedness and relief.

Firmly rooted in a deep commitment to social responsibility and the concept of enlightened self-interest championed by Benjamin Franklin, the philosophy behind Henry Schein Cares is a vision of "doing well by doing good." Through the work of Henry Schein Cares to enhance access to care for those in need, the Company believes that it is furthering its long-term success. To learn more about how Henry Schein Cares is making a difference, please visit: www.henryschein.com/socialresponsibility.

On October 21, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that it will host an investor webcast on Oct. 28, 2020, at 4:30 p.m. Eastern time, to highlight the planned launch of the ConfirmDx-Melanoma test, which will be commercially available in the fourth quarter of 2020 (Press release, Castle Biosciences, OCT 21, 2020, View Source [SID1234568742]). ConfirmDx-Melanoma is designed for use in patients with difficult-to-diagnose suspicious pigmented (melanocytic), lesions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Castle’s ConfirmDx-Melanoma test is designed to aid dermatopathologists in characterizing difficult-to-diagnose pigmented lesions. Of the 2 million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. ConfirmDx-Melanoma classifies these lesions as: benign (gene expression profile suggestive of benign neoplasm); intermediate-risk (gene expression profile cannot exclude malignancy); or malignant (gene expression profile suggestive of malignant melanoma). Interpreted in the context of other clinical, laboratory and histopathologic information, ConfirmDx-Melanoma is designed to add diagnostic clarity and confidence for dermatopathologists, while helping dermatologists better understand the clinical implications for more informed patient care.

Conference call and webcast details can be found below:

Title:

Castle Biosciences ConfirmDx-Melanoma Investor Webcast

Date:

October 28, 2020

Time:

4:30 p.m. ET

Dial-in:

US/Canada Participant Toll-Free Dial-in number: (877) 282-2581

US/Canada Participant International Dial-in number: (470) 495-9137

Conference ID:

4091207

The webcast will include Sarah I. Estrada, M.D., FACP, laboratory director, Affiliated Dermatology, as a guest speaker. There will be a brief Question & Answer session following management commentary.

A live webcast of the conference call can be accessed here View Source or via the webcast link on the Investor Relations page of the Company’s website (www.castlebiosciences.com). Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until Nov.18, 2020.

About Suspicious Pigmented Lesions

In the U.S., approximately 2 million skin biopsies of pigmented or melanocytic lesions are performed annually, leading to the diagnosis of an estimated 130,000 invasive melanoma cases and more than 96,000 in situ melanoma cases. These biopsies are typically pigmented lesions for which the healthcare provider suspects melanoma. The majority of these biopsies receive a definitive diagnosis by the dermatopathologist using traditional microscopic analyses. However, approximately 300,000 biopsies are considered difficult-to-diagnose using this traditional method and require additional testing to clarify the likelihood that this lesion is benign or malignant. And though there are several options for further testing, Castle believes there is a need for improvements in objective tests to resolve this diagnostic dilemma.

On October 21, 2020 NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, reported that it has entered into a second clinical trial collaboration agreement with F. Hoffmann-La Roche (Roche) to evaluate the combination of NeoImmuneTech’s NT-I7 (efineptakin alfa), a novel long-acting IL-7, and Roche’s atezolizumab (Tecentriq), a PD-L1 Checkpoint Inhibitor (CPI) (Press release, NeoImmuneTech, OCT 21, 2020, View Source [SID1234568740]). This new master agreement will now pivot to focus initially on a Phase 2 trial in previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, with the goal to evaluate anti-tumor efficacy and safety of the NT-I7 and atezolizumab combination. The results of this study will be used to further clinical development of this combination.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NT-I7 has the potential to address multiple immune resistance mechanisms by increasing the number of patients’ lymphocytes, expanding T cell repertoire, facilitating the infiltration of cancer-targeting lymphocytes into tumor microenvironments, and sustaining the anti-cancer immune response via memory development," said NgocDiep Le, MD, PhD, Executive Vice President and Chief Medical Officer of NeoImmuneTech (NIT). "As a result, adding NT-I7 to atezolizumab may increase the efficacy of single-agent atezolizumab and broaden the patient population who may benefit from the combination treatment."

"We are excited to enter into a second collaboration agreement with Roche and to continue advancing our T cell enhancer, NT-I7, in the clinic through multiple collaborations with the field’s leading cancer therapeutics such as atezolizumab," added Se Hwan Yang, PhD, Chief Executive Officer of NIT. "NSCLC is the leading cause of cancer deaths worldwide, and we are hopeful that adding NT-I7 to atezolizumab will yield promising results and provide a chemo-free treatment option for these patients."

Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

About NT-I7

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

On October 21, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (Press release, Turning Point Therapeutics, OCT 21, 2020, View Source [SID1234568737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional details are anticipated to be released by IASLC, including presentation titles on Dec. 16 and abstracts on Jan. 12, 2021. For more information, visit View Source